The hypoxic triggered mechanism in cancer is similar in function to hypoxia activated prodrugs (HAPs), meaning drugs that are activated in low-oxygen conditions. In contrast, RRx-001’s 2-stage mechanism, with utility under normal conditions coupled with the hypoxia triggered activity, is what places it apart in a class of its own and supports potential benefit across many therapeutic indications.
RRx-001 initial mechanism
Regulating chronic inflammation
Control inflammation & control the disease
RRx-001 inhibits the inflammasome
RRx-001 in Oncology
In “abnormal” conditions, such as with cancer, RRx-001 generates an alternate mechanism that has shown in preclinical and clinical studies to normalize blood flow in tumors, allowing oxygenation of tumor tissue and modifying the tumor immune environment with reduction in CD47 expression and reprogramming of tumor associated macrophages.